Fresenius Medical Care shares are currently in the red - financial expert analyzes price loss

Fresenius Medical Care shares are currently in the red - financial expert analyzes price loss

According to a report from www.ariva.de,

The Fresenius Medical Care share (Fresenius Medical Care share) is currently experiencing a price loss of 0.37 percent, which corresponds to a minus of 14 cents compared to the last recorded price on the previous trading day.

Fresenius Medical Care is a global market leader in dialysis technology and recently recorded sales of 17.6 billion euros and an annual net profit of 969 million euros. The company therefore has development opportunities due to the increasing need for dialysis technology in the treatment of severe kidney dysfunction associated with the increasing age of the world population.

The shares of competitors DaVita and Baxter are currently recording a slight positive performance, while Roche is recording a slight price loss. The market capitalization of Fresenius Medical Care (11.1 billion euros) is in the middle compared to DaVita (9.25 billion euros) and Baxter (17.1 billion euros).

The US bank JPMorgan has left FMC at “Underweight” with a price target of 28 euros. Analyst David Adlington expects sales momentum to slow and sees little room for improvement in market expectations for margins. He also sees concerns about dialysis provider FMC's long-term sales growth due to the introduction of new weight-loss medications.

Based on these developments, Fresenius Medical Care shares could come under further pressure. JPMorgan's analysis and the slight price losses of its competitors indicate that the company is facing challenges in the market. The current negative trend could impact the medical technology market and competitors' stocks as investors consider the long-term growth prospects of the company and the sector as a whole.